linjc16/ctgov huggingface dataset:
Effect of Paricalcitol Over Vessel Wall

Study Overview
=================
Brief Summary
-----------------
To provide evidence based prospectives of the potential benefit effects of paricalcitol, an analog of vitamin D, over the prevention / retardation of the progression of neoangiogenesis (vessels), atherosclerosis and vascular calcification.

Detailed Description
-----------------
Providing prospective results based on evidence of potential beneficial effects of paricalcitol, an analogue of vitamin D in the prevention / delay of progression of neoangiogenesis (vessels), atherosclerosis and vascular calcification.

Official Title
-----------------
Effect of Paricalcitol Over Vessel Wall: Pleiotropic Analogues Vitamin D Effects

Conditions
-----------------
Nephropathy

Intervention / Treatment
-----------------
* Drug: Paricalcitol


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients aged between 50 and 75 years. Chronic kidney disease stage 5 D or 4-5 No D as calculated glomerular filtration rate (MDRD). Concentration of intact parathyroid hormone (iPTH): 150-400 pg/ml. Plasma concentrations of 25 (OH) vitamin D <30 ng/ml. Without vitamin D supplementation for 3 months before the study. Serum P> 3.8 mg / dl. Serum Ca> 9.8 mg / dl. No history of cardiovascular events (angina or myocardial infarction, stroke, peripheral arterial disease). No exclusion criteria for the use of contrast. Exclusion Criteria: Allergic reaction to sulfur hexafluoride. Recent unstable cardiac symptoms. Patients with recent coronary intervention (<7 days) Patients with class III and IV heart failure or severe arrhythmias. Severe pulmonary hypertension.

Ages Eligible for Study
-----------------
Minimum Age: 50 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Treatment<br>Patient will take one pill of paricalcitol a day. | Drug: Paricalcitol<br> <br> * Other names: Zemplar- 1 ug/day;|
| No Intervention: Usual treatment.<br>Patient allocated to this arm will only take his/her habitual treatment | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevention on vessels progression based on paricalcitol intake. | Providing prospective results based on evidence of potential beneficial effects of paricalcitol, an analogue of vitamin D in the prevention / delay of progression of neoangiogenesis (vessels), atherosclerosis and vascular calcification. | participants will be followed for the duration of whole study, an expected average of 1 year |
Validation of the Screening Instrument: PRISMA-7 for Frailty Among Elderly Hospitalized Danes

Study Overview
=================
Brief Summary
-----------------
The questionnaire PRISMA-7 was originally developed to assess frailty in community dwelling adults. The questionnaire was translated into the Danish language. This instrument was used to screen for frailty among elderly patients (75+) sent home from Nykøbing Falster Hospital after a hospital admission during the period 31. May 2017 until December 31st, 2018. PRISMA results were used to categorize each individula as frail or non-frail. The register of PRISMA results was merged with national registers on use of health serviced in order to investigate if increasing PRISMA score was associated with increasing use of health services.

Detailed Description
-----------------
Data from PRISMA scores were registered in an EasyTrial database. This database is recognized by the regional health authorities as a safe system to store individual health data. All use of the EasyTRial database is logged. The merging of data from the local EasyTRial database with data from national registries on use of health services and on mortality was permitted by the Danish National Health Data protection authorities.

Official Title
-----------------
Validation of the Screening Instrument: PRISMA-7 for Frailty Among +75 Year Old Danes Still in Need of Physical Training When They Are Sent Home After a Hospital Stay

Conditions
-----------------
Frailty Syndrome

Intervention / Treatment
-----------------
* Diagnostic Test: PRISMA score


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 75 years old persons being returned from hospital after a hospital admission and in need of further physical rehabilitation in the community Exclusion Criteria: Not able to give informed consent or if necessary not having a relative that can give informed consent

Ages Eligible for Study
-----------------
Minimum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: PRISMA score|Screening for frailty using PRISMA-7|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mortality | Mortality | 6 months after PRISMA-7 screening | 
| Morbidity | Morbidity will be measured by registering Hospital admissions and use of general practitioner | 6 months after Prisma-7 screening | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Use of other health services | Home help, rehabilitation services in the municipality | 6 months before PRISMA-7 screening | 
| Morbidity | Morbidity will be measured by registering hospital admissions and use og general practitioner | 6 months after PRISMA-7 screening |
Urinary Proteomics Analysis for Sepsis and Prognosis

Study Overview
=================
Brief Summary
-----------------
As a noninvasive examination, urinary proteomics is a very useful tool to identify renal disease. The purpose of the present study was to find differential proteins among patient with SIRS and sepsis(included survivors and non-survivors), and to screen potential biomarkers for the early diagnosis of sepsis and its prognosis. Urinary proteins were identified by iTRAQ labeling and LC-MS/MS. The bioinformatics analysis was performed with the Mascot software and the International Protein Index (IPI) and the Gene Ontology (GO) Database and KEGG pathway Database. The differentially expressed proteins were verified by Western blot by another sample collected from clinical.

Official Title
-----------------
Urinary Proteomics Analysis for Sepsis Identification and Its Prognosis in Sepsis Patient With iTRAQ Labeling and and LC-MS/MS

Conditions
-----------------
SIRS, Sepsis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male and female aged 18 years old and over; clinically confirmed infection; fulfilled at least two criteria of systemic inflammatory response syndrome (a) core temperature higher than 38 °C or lower than 36 °C (b)respiratory rate above 20/min, or PCO2 below 32 mmHg (c) pulse rate above 90/min, and (d) white blood cell count greater than 12,000/μl or lower than < 4,000/μl or less than 10% of bands. Exclusion Criteria: younger than 18 years of age; acquired immunodeficiency syndrome; reduced polymorphonuclear granulocyte counts (< 500 μL-1); died within 24h after admission into the ICU, or refused to participate in the study, or declined treatment during the period of observation.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| SIRS<br>temperature >38 ℃ or <36℃; pulse rate>90 beats/min; ventilatory rate>20 breaths/min or hyperventilation with partial pressure of arterial carbon dioxide (PaCO2)<32mmHg; white blood cell count>12,000μL-1 or <4000μL-1 or >10% immature cells | |
| sepsis<br>Sepsis sepsis: SIRS plus infection; severe sepsis: sepsis associated with organ dysfunction, hypoperfusion, or hypotension; septic shock: sepsis with arterial hypotension, despite adequate ﬂuid resuscitation. | |
| non-survivors with sepsis<br>sepsis patients who died within 28 days | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Survival status | The survival time of patients more than 28days is defined as survival. The survival time of patients less than 28days is defined as death | 28days after admited in ICU | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
proteomics,urinary,sepsis,prognosis
Evaluation of Circadian Variation of EEG Using BIS Monitor in ICU Patients

Study Overview
=================
Brief Summary
-----------------
The investigators propose to evaluate circadian variation of EEG using BIS (bispectral index) monitor in ICU patients in three different groups: non-sedated, only sedated and sedated and curarized. BIS monitor values as SR (suppression rate), SEF (Spectral edge frequency), bispectral index and EMG (electromyography) during 24 hours in admitted patients except acute neurological disease.

Conditions
-----------------
EEG Circadian Variation of ICU Patients

Intervention / Treatment
-----------------
* Device: BIS monitor


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Admitted in the ICU Over 18 years old Exclusion Criteria: Acute neurological disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Awake patients<br>Awake patients | Device: BIS monitor<br>* Monitoring circadian variation of EEG<br>|
| Sedated patients<br> | Device: BIS monitor<br>* Monitoring circadian variation of EEG<br>|
| Sedated and curarized patients<br> | Device: BIS monitor<br>* Monitoring circadian variation of EEG<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Circadian EEG variation |  | 24 hours |
Retrospective Patient Satisfaction Survey in Subjects With Tecnis Intra Ocular Lenses and Cataracts Surgery

Study Overview
=================
Brief Summary
-----------------
Define what factors correlate with higher degrees of patient satisfaction and dissatisfaction among patients who have recently undergone cataract surgery.

Official Title
-----------------
Retrospective Patient Satisfaction Survey in Subjects With Tecnis Intra Ocular Lenses Cataracts Surgery

Conditions
-----------------
Cataract

Intervention / Treatment
-----------------
* Procedure: Cataract Surgery


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with uncomplicated bilateral cataract surgery with a Tecnis Multifocal or monofocal implant completed at least 60 days before the survey date. Patient with and without astigmatic keratotomy will be included. Exclusion Criteria: Patients with visually significant co-morbidities (corneal, retina, optic nerve disease) that could affect their satisfaction with surgery Patients with surgical complications either during or after surgery (capsule tears, iris trauma, decentered IOL, cystoid macular edema, etc.) Patients with ≥ grade 1 posterior capsule opacity at their last visit

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Cataract Surgery<br> | Procedure: Cataract Surgery<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patient overall satisfaction post Cataract surgery | Patient will be given a satisfaction survey based on overall satisfaction: Motivations for choosing their surgeon and for selecting an IOL choice Fears that they had before surgery Degree of spectacle independence for activities, including driving (day and night), watching television, computer use, reading print material, using their mobile phone Degree of overall satisfaction with vision Degree to which they notice unexpected side effects (dysphotopsias) Degree to which they felt informed about any side effects they did experience Activities for which they would like to see better Willingness to refer friends for the same surgery Whether they have already referred friends for the same surgery | 60 plus days Post surgery |
Clinical Evaluation of Mediguide System in Cardiac Resynchronization Therapy (CRT) Implants

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the safety and performance of the MediGuide™ system during CRT implants.

Official Title
-----------------
Clinical Evaluation of Mediguide System in CRT Implants

Conditions
-----------------
Heart Failure

Intervention / Treatment
-----------------
* Device: MediGuide™


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Meet clinical indication for implantation of an SJM CRT system according to the current European Society of Cardiology (ESC) Guidelines for cardiac and resynchronization therapy Receiving a new implant or undergoing an upgrade from an existing ICD or pacemaker implant with no prior LV lead placement Ability to provide informed consent for study participation and are willing and able to comply with the prescribed follow-up tests and schedule of evaluations Exclusion Criteria: Currently participating in any other clinical study Have prosthetic valves Are pregnant or planning pregnancy in the next 1 month Are less than 18 years of age Have ventricular tachyarrhythmias resulting from transient or correctable factors such as drug toxicity, electrolyte imbalance, or acute myocardial infarction

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: MediGuide Arm<br> | Device: MediGuide™<br>* MediGuide™ system will be used to guide CRT implants<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The performance of the MediGuide™ system during CRT implant | Performance will be assessed in terms occurence of adverse events, easy of use and potential benefits. | 1 month post CRT implant |
Dual Energy CT vs Standard Triple Phase CT-A Randomised Control Trial

Study Overview
=================
Brief Summary
-----------------
To compare SBDECT with standard Triple Phase Multi-Detector CT (TPMDCT) in renal mass evaluation in terms of appropriateness of treatment received after diagnosis. To determine SBDECT diagnostic accuracy.

Official Title
-----------------
Role of Split Bolus Dual Energy Single Acquisition CT in Evaluation of Urological Diseases of the Upper Urinary Tract.

Conditions
-----------------
Renal Cell Carcinoma, Renal Cysts, Transitional Cell Carcinoma, AML

Intervention / Treatment
-----------------
* Other: Standard multiphase CT
* Other: split bolus Dual energy CT


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with suspected renal masses needing further evaluation with a contrast enhanced CT scan Patients who are referred for CT Urography Exclusion Criteria: Patients not willing to participate in the study Age <18 yrs Pregnant females Patients with previous h/o serious allergic reactions or Contrast allergy Impaired renal function (estimated GFR<45mL/min/mm2) Sonographically proven benign renal mass needing no further evaluation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: split bolus<br>Patients will undergo diagnostic Split bolus DECT scan | Other: split bolus Dual energy CT<br> <br> |
| Experimental: Standard<br>Patients will undergo routine multiphase diagnostic CT | Other: Standard multiphase CT<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Appropriateness of the treatment recieved |  | 1 year |
The Purpose of the Study is to Gain an In-depth Picture of the Patient Management and Prescription Behaviours

Study Overview
=================
Brief Summary
-----------------
'Real life' retrospective patient cases (10) to provide an objective and robust analytical report of patient management and prescriptions behaviours for Schizophrenia, Bipolar disorders and Major depressive disorders.

Official Title
-----------------
The Purpose of the Study is to Gain an In-depth Picture of the Patient Management and Prescription Behaviours

Conditions
-----------------
Schizophrenia, Bipolar Disorders, Major Depressive Disorders

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients diagnosed with one of the following conditions: Schizophrenia, Bipolar disorders and Major depressive disorders. Exclusion Criteria: Patients who have not been diagnosed with the conditions as outlined in the Inclusion criteria.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Rectal Cancer Trial On Defunctioning Stoma

Study Overview
=================
Brief Summary
-----------------
The hypothesis of the present trial was that the use of a defunctioning loop stoma reduces the rate of symptomatic anastomotic leakage from 15% to 7.5% after low anterior resection of the rectum for cancer.

Detailed Description
-----------------
The assumption that a defunctioning loop stoma reduces symptomatic anastomotic leakage from 15% to 7.5%, with a level of statistical significance of 5% and a statistical power of 80%, requires randomization of 220 patients.

Official Title
-----------------
Rectal Cancer Trial On Defunctioning Stoma

Conditions
-----------------
Rectal Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Absence of intraoperative adverse events according to the study protocol and the operating surgeon. Exclusion Criteria: Presence of intraoperative adverse events according to the study protocol and the operating surgeon.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Symptomatic anastomotic leakage following low anterior resection of the rectum for cancer with and without a defunctioning stoma. Anorectal function after one and five years without defunctioning stoma. |  | 30 days, one year and five years. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Reoperation within 30 days of initial surgery. |  | 30 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Rectal cancer surgery, Symptomatic anastomotic leakage, Defunctioning stoma, TME surgery
Effect of Acupuncture on Anti Mullerian Hormone and Assisted Reproduction Outcome in PCOS Patients Undergoing IVF

Study Overview
=================
Brief Summary
-----------------
Acupuncture at follicular phase of the cycle may improve the pregnancy rate. This study aims to compare assisted reproduction outcome between two groups of PCOS patients underwent IVF, one group received acupuncture and other group without acupuncture.

Detailed Description
-----------------
Follicular phase acupuncture applied for PCOS patients underwent IVF to evaluate the effect of acupuncture on anti-mullerian hormone (AMH) and the effect on assisted reproduction outcome. It applied at certain acupoints according to the principles of traditional Chinese medicine.

Official Title
-----------------
Acupuncture Treatment Versus Non-acupuncture During IVF

Conditions
-----------------
PCOS

Intervention / Treatment
-----------------
* Device: Acupuncture(Hwato®)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria:: PCOS patients with patent one or two fallopian tubes, normal uterine cavity and partners with normal semen parameters. infertility 20-40 years IVF treatment - Exclusion Criteria: patients with disorders that have the similar clinical presentation closed both tubes abnormal semen parameters intracytoplasmic sperm injection (ICSI)

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Acupuncture (Hwato®)<br>30-40 minutes acupuncture at certain acupoints that chosen according to traditional Chinese medicine and included LIV3,SP6,SP8,ST36,SP10,ST29,LI14,Ren 04;starting at follicular phase of the cycle till 2 days before oocyte picked up. | Device: Acupuncture(Hwato®)<br>* acupuncture using 4cm long disposable stainless steel hair-thin needles manufactured by Suzhou medical appliance factory (China).<br>|
| No Intervention: No acupuncture<br>No intervention was done for this group of patients. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical pregnancy rate. | Increase in pregnancy rate | 13 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ongoing pregnancy rate | Increase in ongoing pregnancy rate | 15 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
AMH, Acupuncture, PCOS